Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome

NCT00001852 | Completed

• 2 other identifiers: 99007099-D-0070
• Study Type: observational
• Target: 560
• Locations: 1 country
• Sites: 1

Brief Summary

This study will follow patients with salivary gland dysfunction to identify the long-term course of this disorder and its effects on the mouth, oral function, and overall health. Saliva is important in maintaining oral health and comfort. It moistens the mouth, lubricates food for easier swallowing, provides enzymes needed to begin the digestive process and promotes repair and cleansing of soft tissues of the mouth. Decreased salivary production or changes in salivary composition may affect oral and systemic health and cause an increase in tooth decay. Patients 4 years of age and older with dry mouth symptoms and a diagnosis of primary, secondary or incomplete Sj(SqrRoot)(Delta)gren s syndrome or salivary gland dysfunction due to radiation may be eligible for this study. Candidates will be screened with a complete medical and dental history and blood and saliva tests. Some patients will have a biopsy of the minor salivary glands, usually from the lower lip, to confirm or rule out the diagnosis of Sj(SqrRoot)(Delta)gren s syndrome and determine the extent of changes in the salivary glands. (A biopsy is the surgical removal of a small piece of tissue for laboratory examination.) The ability to taste and smell may also be evaluated, and patients may have an ultrasound examination of their swallowing function. Participants will have a general oral examination of the teeth and soft tissues of the mouth, general physical examination, eye examination and blood tests and will fill out a questionnaire on oral health and function. In addition, they will have the following tests and procedures:

• Identification of possible fungal infection Patients rinse their mouth with 2 teaspoons of a salt-water solution and spit it in a sterile container for laboratory examination. If a fungal infection is detected, treatment will be offered.
• Unstimulated salivary function assessment Saliva production is measured by collecting saliva samples through small suction cups connected to collection tubes over the salivary gland ducts in the mouth.
• Stimulated salivary function assessment A sour-tasting liquid (2% citric acid) is applied to the top and sides of the tongue at 30-second intervals to stimulation saliva production while saliva is collected using the procedure described above.
• Identification of markers of precancerous lesions The salivary gland biopsy done at the screening evaluation (or from outside sources) is examined for markers of precancerous lesions, as about 5 percent of patients with Sj(SqrRoot)(Delta)gren's syndrome develop a tumor called Non-Hodgkin s lymphoma. In some cases, the minor salivary glands may be re-biopsied a few years after the screening biopsy. Patients will be followed once a year with a comprehensive history and physical examination, eye examination, full oral examination, salivary function assessment and questionnaires about signs and symptoms of salivary gland dysfunction.

Conditions

Lymphoma; Salivary Gland Disease; Sjogren's Syndrome; Xerostomia

Keywords

Xerostomia; Oral Dryness; Salivary Function

Eligibility Criteria

• Age: 4 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects.
• All subjects will have first participated in screening protocol 84-D-0056 to confirm their diagnosis and assess salivary function.
• Subjects must have dry mouth symptoms (xerostomia) and a diagnosis of primary or secondary SS, incomplete SS, or radiation-induced salivary gland dysfunction (as determined in protocol 84-D-0056).
• Diagnostic criteria for SS are the American-European Consensus Group Classification Criteria: For primary Sjogren s syndrome, any 4 of the 6 criteria, must include item IV (Histopathology) or VI (Auto-antibodies) or any 3 of the 4 objective criteria (III, IV, V, VI). For secondary Sjogren s syndrome, must have established connective tissue disease, one symptom (I or II) plus 2 of the 3 objective criteria (III, IV, VI).
• Ocular symptoms (at least one)
• Daily persistent dry eyes for greater than 3 months?
• Recurrent sensation of sand or gravel in the eyes?
• Use of tear substitutes greater than 3 x/day?
• Oral symptoms (at least one)
• Daily feeling of dry Mouth greater than 3 months
• Recurrent or persistently swollen salivary glands as an adult?
• Frequently drink liquids to aid in swallowing dry foods?
• Ocular signs (at least one)
• Schirmer s test, (without anesthesia) greater than or equal to 5mm/5 minutes
• Positive vital dye staining (van Bijsterveld greater than or equal to 4)

You may not qualify if:

• Past head and neck radiation treatment
• Hepatitis C infection
• Acquired Immunodeficiency Syndrome (AIDS)
• Pre-existing lymphoma
• Sarcoidosis
• Graft versus host disease
• Current use of anticholinergic drugs
• Failure to complete evaluation procedures as specified in 84-D-0056.
• Diagnosis of drug-related xerostomia.
• Age less than 4 years.
• ULTRASOUND GUIDED CORE NEEDLE BIOPSY OF THE PAROTID GLAND
• Adult subjects already enrolled in this protocol and healthy volunteers will be eligible for this research procedure if they fulfill the criteria below and sign the parotid biopsy consent form. Healthy volunteers will be recruited only for the ultrasound guided core needle biospy of the parotid gland. They will sign the parotid biopsy consent form only.
• Age 18 years or older.
• Ability to give informed consent.
• History of bleeding diathesis or the current use of anticoagulants.

Sponsors & Collaborators

• National Institute of Dental and Craniofacial Research (NIDCR): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (4)

• Anaya JM, Ogawa N, Talal N. Sjogren's syndrome in childhood. J Rheumatol. 1995 Jun;22(6):1152-8.

  PMID: 7674246 BACKGROUND

• Andonopoulos AP, Tiniakou M, Melachrinou M, Sfountouris H, Bounas A, Zervas C, Zoumbos NC. Sjogren's syndrome in patients with newly diagnosed untreated non-Hodgkin's lymphoma. Rev Rhum Engl Ed. 1997 May;64(5):287-92.

  PMID: 9190001 BACKGROUND

• Atkinson JC, Travis WD, Slocum L, Ebbs WL, Fox PC. Serum anti-SS-B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary Sjogren's syndrome. Arthritis Rheum. 1992 Nov;35(11):1368-72. doi: 10.1002/art.1780351119.

  PMID: 1445455 BACKGROUND

• Alevizos I, Alexander S, Turner RJ, Illei GG. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum. 2011 Feb;63(2):535-44. doi: 10.1002/art.30131.

  PMID: 21280008 DERIVED

MeSH Terms

Conditions

Lymphoma; Salivary Gland Diseases; Sjogren's Syndrome; Xerostomia

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Mouth Diseases; Stomatognathic Diseases; Arthritis, Rheumatoid; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Dry Eye Syndromes; Lacrimal Apparatus Diseases; Eye Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases

Study Officials

• Ilias G Alevizos, D.M.D.

  National Institute of Dental and Craniofacial Research (NIDCR)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 3, 1999
• First Posted: November 4, 1999
• Study Start: April 9, 1999
• Study Completion: November 29, 2017
• Last Updated: December 17, 2019

Record last verified: 2017-11-29

Locations

US (1)